Clincosm LogoSign in Get a demo

RALOX or CAPOX + Bevacizumab in the First-line Treatment of Advanced CRC(ROCB Study)

Sponsor
Shenzhen People's Hospital (Other)
Overall Status
Unknown status
CT.gov ID
NCT03813641
Collaborator
(none)
100
Enrollment
1
Location
2
Arms
35.1
Anticipated Duration (Months)
2.8
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

Raltitrexed is an inhibitor of thymidylate synthase.As a folate antimetabolite drug, raltitrexed has been used in treatment of colorectal cancer(CRC) since 1998, and also used in malignant mesothelioma.Several phase III studies performed in patients with advanced CRC showed that it is as effective as 5-fluorouracil(5-FU) /leucovorin(LV) with regard to response rates and survival. The combination of raltitrexed with oxaliplatin shows response rates of 41%-54% and median survivals of 14.6-14.8 months, which are comparable to those achieved with 5-FU/LV combination with oxaliplatin. This study discussed the efficacy and safety of raltitrexed-oxaliplatin(RALOX) combined with bevacizumab or capecitabine-oxaliplatin(CAPOX) combined with bevacizumab in first-line treatment of patients with advanced colorectal cancer who could not undergo radical surgery. The main endpoint will be progression free survival (PFS). The secondary endpoints will be overall survival, objective response rate and disease control rate (OS,ORR and DCR).It is expected that raltitrexed may be one of options for the treatment of advanced CRC in the first-line setting.

Condition or Disease Intervention/Treatment Phase
Phase 2

Detailed Description

According to the inclusion and exclusion criteria, the patients will be randomly divided into two groups: the experimental group (group A) will be administered with raltitrexed 3mg/m2 intravenously combined with oxaliplatin and bevacizumab, repeated every 21 days. The control group (group B) will be administered with orally capecitabine (1000mg/m2, d 1-14) combined with oxaliplatin and bevacizumab, repeated every 21 days. After 8 cycles of treatments, if evaluated as complete response(CR),partial response(PR) or stable disease(SD), CRC patients will go into maintenance therapy wtih raltitrexed combined with bevacizumab in group A or capecitabine combined with bevacizumab in group B respectively, ended in disease progression(PD) , symptoms deterioration, unacceptable toxicity, death or withdrawal of consent (whichever occurs first). The radiological efficacy will be evaluated every 6 weeks (2 treatment cycles) and non-PD (PD criteria referring to RECIST 1.1 criteria) patients will continue to be treated until the cancer progression or the patient's intolerable toxicity or death. Toxic side effects and quality of life will be assessed at the same time.

Follow up participants and analyse primary endpoint (PFS) and secondary endpoints (OS,ORR and DCR).The causes of confirmed missing data in the trial should be recorded in detail to determine the mechanism of missing data and choose the suitable missing data handling methods.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
100 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
Randomized controlled trialRandomized controlled trial
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Phase Ⅱ Clinical Study of RALOX or CAPOX Combined With Bevacizumab in the First-line Treatment of Advanced Colorectal Cancer
Actual Study Start Date :
Jan 28, 2019
Anticipated Primary Completion Date :
Feb 28, 2021
Anticipated Study Completion Date :
Dec 31, 2021

Arms and Interventions

Arm Intervention/Treatment
Experimental: RALOX + bevacizumab

Oxaliplatin 130mg/m2, i.v.gtt 2h, d1 Raltitrexed 3mg/m2, i.v.gtt 15min ,d1 Bevacizumab 7.5mg/kg, i.v.gtt, d1 The above schemes are repeated every three weeks. After 8 cycles, such as CR, PR or SD, the regimen is changed to raltitrexed (3mg/m2, intravenous drip for 15 minutes, d1)+bevacizumab (7.5mg/kg, intravenous drip, d1). The regimen is repeated every 3 weeks until the disease progresses.

Drug: Raltitrexed
Experimental: Oxaliplatin + Raltitrexed + Bevacizumab The above schemes are repeated every three weeks. After 8 cycles, such as CR, PR or SD, the regimen is changed to Raltitrexed (3mg/m2, intravenous drip for 15 minutes, d1)+bevacizumab (7.5mg/kg, intravenous drip, d1). The regimen is repeated every 3 weeks until the disease progresses.
Other Names:
  • Tomudex

    		•
    Active Comparator: CAPOX + bevacizumab

    Oxaliplatin 130mg/m2, i.v.gtt 2h, d1 Capecitabine 1000mg/m2, po. ,d1 Bevacizumab 7.5mg/kg, i.v.gtt, d1 The above schemes are repeated every three weeks. After 8 cycles, such as CR, PR or SD, the regimen is changed to Capecitabine (1000mg/m2 po. d1-14)+bevacizumab (7.5mg/kg, intravenous drip, d1). The regimen is repeated every 3 weeks until the disease progresses.

    Drug: Capecitabine
    Other: Oxaliplatin + Capecitabine + Bevacizumab The above schemes are repeated every three weeks. After 8 cycles, such as CR, PR or SD, the regimen is changed to Capecitabine (1000mg/m2 po. d1-14)+bevacizumab (7.5mg/kg, intravenous drip, d1). The regimen is repeated every 3 weeks until the disease progresses.
    Other Names:
  • Xeloda

    		•

    Outcome Measures

    Primary Outcome Measures

    1. Progression-free Survival (PFS) Time [The follow-up period ranges from the first patient recruited to the last patient within 6 months after admission, up to 2 years.]

      PFS is defined as the time from the date of randomization until the date of objectively determined progressive disease (PD) [according to Response Evaluation Criteria in Solid Tumors (RECIST) version (v). 1.1] or death due to any cause, whichever will be first. PD is at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 millimeters (mm). Participants who died without a reported prior progression will be considered to have progressed on the day of their death. Participants who do not progress or be lost to follow-up will be censored at the day of their last radiographic tumor assessment.

    Secondary Outcome Measures

    1. Overall Survival (OS) [The follow-up period ranges from the first patient recruited to the last patient within 6 months after admission,up to 2 years.]

      OS is defined as the time in months from the date of randomization to the date of death from any cause. For participants not known to have died as of the cut-off date, OS will be censored at the last known date alive.

    2. Percentage of Participants Achieving an Objective Response (Objective Response Rate) [The follow-up period ranges from the first patient recruited to the last patient within 3 months after admission.]

      The objective response rate is equal to the proportion of participants achieving a best overall response of partial response or complete response (PR + CR). Response is defined using RECIST, v. 1.1 criteria. CR is defined as the disappearance of all target and non-target lesions and any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm and normalization of tumor marker level of non-target lesions; PR is defined as having at least a 30% decrease in sum of longest diameter of target lesions taking as reference the baseline sum diameter.

    3. Percentage of Participants Achieving a Stable Disease (SD) or a confirmed CR or PR (Disease Control Rate) [The follow-up period ranges from the first patient recruited to the last patient within 3 months after admission.]

      Participants achieved disease control if they have a best overall response of CR, PR or SD. According to RECIST v1.1, CR is the disappearance of all non-nodal target lesions, with the short axes of any target lymph node reduced to <10 mm, the disappearance of all non-target lesions, and the normalization of tumor marker levels (if tumor markers were initially above the ULN); PR was defined as at least a 30% decrease in the sum of the diameters of target lesions (including the short axes of any target lymph node), taking as reference the baseline sum diameter. SD is neither sufficient shrinkage to qualify as PR nor sufficient increase to qualify as PD, taking as reference the smallest sum diameter since treatment started.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 75 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:

    • Age 18~75 years;

    • Patients are diagnosed by histopathological and/or cytological examination as local advanced or metastatic colorectal cancer who are unable to undergo radical surgery with no symptom of the primary lesions；

    • There are one or more measurable lesions, the longest diameter of which is at least 10 mm by spiral CT scanning (RECIST standard, version 1.1)

    • ECOG performance status (ECOG PS) 0~1;

    • Life expectancy not less than 3 month

    • Blood routine, liver and kidney function reached the following criteria within 14 days before screening:

    Absolute neutrophil count (> 1.5x109/L); hemoglobin (> 9.0 g/dl); platelet count (> 100 x109/L); total bilirubin (< 1.5 times the normal upper limit (ULN); alanine aminotransferase and glutamic oxaloacetate aminotransferase (< 2.5 x ULN) in patients with liver metastasis (< 5 x ULN); alkaline phosphatase （< 3 x ULN（ in patients with liver metastasis < 5 x ULN)）; serum creatinine （< 1.5 x ULN）;

    • Adequate blood coagulation function [International Normalized Ratio (INR) ≤1.5 and Partial Thromboplastin Time (PTT) or activated PTT (aPTT) ≤1.5 x upper limit of normal (ULN)). Participants on full-dose anticoagulation must be in a stable phase of anticoagulant therapy and if taking oral anticoagulation, participants must have an INR ≤3 without clinically significant active bleeding or a high risk of bleeding.

    • Agree to provide histological specimens from previous operations for biomarker assessment and specimens remain。

    • Signed informed consent to be provided

    Exclusion Criteria:

    • Previous treatment with Raltitrexed；

    • With a large amount of pleural effusions or ascites requiring puncture drainage；

    • Active clinical severe infections include hepatitis；

    • One of the following complications: 1) Gastrointestinal obstruction (including paralytic ileus) or gastrointestinal bleeding 2) Symptomatic cardiac disease (including unstable angina, myocardial infarction, and heart failure) 3) Pulmonary fibrosis or interstitial pneumonia 4) Uncontrolled diabetes mellitus 5) Uncontrolled diarrhea (that affects daily activities although adequate therapy )

    • Symptomatic brain or meningeal metastasis (unless the patient has been treated for > 6 months, the imaging results are negative in the 4 weeks before entering the study, and the clinical symptoms associated with the tumor are stable at the time of entering the study);

    • Undergoing kidney dialysis；

    • History of other malignant tumors within 5 years, except for cured cervical carcinoma in situ or basal cell carcinoma of the skin;

    • Drug abuse and medical, psychological or social conditions may interfere with patients' participation in the study or have an impact on the evaluation of the study results；

    • Pregnant or lactating females, and males and females reluctant to use contraception

    • History of concurrent gastrointestinal perforation or gastrointestinal perforation within 1 year prior to enrollment

    • Pulmonary hemorrhage/hemoptysis ≥ Grade 2 (identified as bright red blood of not less 2.5mL) within 1 month before enrollment.

    • History of thoracotomy,laparotomy, or intestinal resection within 28 days prior to enrollment;

    • Unhealed wound (other than suture wounds due to implantation of a central venous port), traumatic fracture, or gastrointestinal ulcer

    • Current cerebrovascular disease or thromboembolism or either within 1 year before enrollment

    • Current anticoagulation therapy or requiring anticoagulation agents (> 325 mg/day of aspirin)

    • Bleeding diathesis, coagulopathy, or coagulation factor abnormality (INR ≥1.5 within 14 days before enrollment)

    • Uncontrolled hypertension

    • Urine dipstick for proteinuria >+2

    • Researchers think those should be excluded

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Shenzhen People's Hospital Shenzhen Guangdong China

    Sponsors and Collaborators

    • Shenzhen People's Hospital

    Investigators

    • Principal Investigator: Ruilian Xu, MD, Shen Zhen People's Hospital

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    Ruilian Xu, Phase Ⅱ Clinical Study of RALOX or CAPOX Combined With Bevacizumab in the First-line Treatment of Advanced Colorectal Cancer, Shenzhen People's Hospital
    ClinicalTrials.gov Identifier:
    NCT03813641
    Other Study ID Numbers:
    • Shenzhen CRC-002
    First Posted:
    Jan 23, 2019
    Last Update Posted:
    Sep 9, 2019
    Last Verified:
    Sep 1, 2019
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Ruilian Xu, Phase Ⅱ Clinical Study of RALOX or CAPOX Combined With Bevacizumab in the First-line Treatment of Advanced Colorectal Cancer, Shenzhen People's Hospital
    Raltitrexed
    First-line therapy
    Bevacizumab
    Colorectal Cancer
    Additional relevant MeSH terms:
    Colorectal Neoplasms
    Capecitabine
    Raltitrexed

    Study Results

    No Results Posted as of Sep 9, 2019